Citations

Showing 10 of 108083 citations.

Characterization of isolated amyloid myopathy
Liewluck, Teerin , Milone, Margherita , Liewluck, T , Milone, M

Mayo Clinic

European Journal of Neurology | September 9, 2017 | Volume: 24 | Issue: 12 | Pages: 1437-1445

10.1111/ene.13448 | PMID 28888072 Get It

Background and purpose Amyloid myopathy frequently occurs in the setting of systemic amyloidosis and less commonly in isolation (isolated amyloid myopathy). Anoctaminopathy‐5 and dysferlinopathy were recently recognized as causes of isolated amyloid myopathy. The present study aimed to characterize the isolated amyloid myopathy and to compare it with amyloid myopathy associated with systemic amyloidosis. Methods We searched the Muscle Laboratory database to identify patients with pathologically confirmed amyloid myopathy seen in neurology clinics between January 1998 and September 2016. Patients with monoclonal gammopathy, peripheral neuropathy, organomegaly or symptoms or pathologic evidence of amyloid deposition outside skeletal muscle were classified as having systemic amyloidosis‐associated myopathy. Results Fifty‐two patients were identified, including 14 with isolated amyloid myopathy (eight anoctaminopathy‐5, two dysferlinopathy and four genetically unknown) and 38 with systemic amyloidosis (32 immunoglobulin light‐chain amyloidosis, four familial amyloid polyneuropathy and two senile systemic amyloidosis). Compared with patients with systemic amyloidosis, patients with isolated amyloid myopathy had a younger age of onset (median, 41.5 vs. 65 years), no dysphagia (0% vs. 26%) or weight loss (0% vs. 26%), but more frequent calf atrophy (57% vs. 0%), small collections of inflammatory cells on muscle biopsy (43% vs. 0%) and asymptomatic hyper CK emia at onset (21% vs. 0%). All patients with isolated amyloid myopathy had creatine kinase (CK) values >2.5 times the upper limit of normal. Conclusions Isolated amyloid myopathy accounts for 27% of patients with amyloid myopathy, mostly due to anoctaminopathy‐5. There are various clinical and laboratory parameters that can help to differentiate isolated amyloid myopathy from systemic amyloidosis.
Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos)
Mori, Yasuhisa , Itoi, Takao , Baron, Todd H. , Takada, Tadahiro , Strasberg, Steven M. , Pitt, Henry A. , Ukai, Tomohiko , Shikata, Satoru , Noguchi, Yoshinori , Kim, Myung‐Hwan , Asbun, Horacio J. , Endo, Itaru , Yokoe, Masamichi, Miura, Fumihiko, Okamoto, Kohji , Umezawa, Akiko , Iwashita, Yukio , Hibi, Taizo , Wakabayashi, Go , Choi, In‐Seok , Hwang, Tsann‐Long , Chen, Miin‐Fu , Garden, O. James , Singh, Harjit , Liau, Kui‐Hin, Huang, Wayne Shih‐Wei, Gouma, Dirk J., Belli, Giulio, Dervenis, Christos, Santibáñes, Eduardo de , Giménez, Mariano , Windsor, John A. , Lau, Wan Yee , Cherqui, Daniel , Jagannath, P., Supe, Avinash , Liu, Keng‐Hao, Su, Cheng‐Hsi, Deziel, Daniel J., Fan, Sheung Tat , Ker, Chen‐Guo , Jonas, Eduard , Padbury, Robert , Sugioka, Atsushi , Asai, Koji , Higuchi, Ryota , Wada, Keita, Yoshida, Masahiro , Mayumi, Toshihiko , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Teoh, Anthony Yuen Bun , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Chen, Xiao‐Ping , Mukai, Shuntaro , Honda, Goro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | September 9, 2017 | Volume: 25 | Issue: 1 | Pages: 87-95

10.1002/jhbp.504 | PMID 28888080 Get It

Abstract Since the publication of the Tokyo Guidelines in 2007 and their revision in 2013, appropriate management for acute cholecystitis has been more clearly established. Since the last revision, several manuscripts, especially for alternative endoscopic techniques, have been reported; therefore, additional evaluation and refinement of the 2013 Guidelines is required. We describe a standard drainage method for surgically high‐risk patients with acute cholecystitis and the latest developed endoscopic gallbladder drainage techniques described in the updated Tokyo Guidelines 2018 ( TG 18). Our study confirmed that percutaneous transhepatic gallbladder drainage should be considered the first alternative to surgical intervention in surgically high‐risk patients with acute cholecystitis. Also, endoscopic transpapillary gallbladder drainage or endoscopic ultrasound‐guided gallbladder drainage can be considered in high‐volume institutes by skilled endoscopists. In the endoscopic transpapillary approach, either endoscopic naso‐gallbladder drainage or gallbladder stenting can be considered for gallbladder drainage. We also introduce special techniques and the latest outcomes of endoscopic ultrasound‐guided gallbladder drainage studies. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Characterization of proton pencil beam scanning and passive beam using a high spatial resolution solid‐state microdosimeter
Tran, Linh T. , Chartier, Lachlan, Bolst, David , Pogossov, Alex , Guatelli, Susanna , Petasecca, Marco , Lerch, Michael , Prokopovich, Dale A., Reinhard, Mark I., Clasie, B. , Depauw, Nicolas , Kooy, Hanne M., Flanz, J., McNamara, Aimee L. , Beltran, Chris , Perevertaylo, Vladimir L. , Jackson, Michael , Rosenfeld, Anatoly , Furutani, Keith, Guatelli, S , Rosenfeld, A B , Beltran, Chris J , Paganetti, Harald , Furutani, Keith M.

Mayo Clinic

Medical Physics | September 9, 2017 | Volume: 44 | Issue: 11 | Pages: 6085-6095

10.1002/mp.12563 | PMID 28887837 Get It

PurposeThis work aims to characterize a proton pencil beam scanning (PBS) and passive double scattering (DS) systems as well as to measure parameters relevant to the relative biological effectiveness (RBE) of the beam using a silicon on insulator (SOI) microdosimeter with well‐defined 3D sensitive volumes (SV). The dose equivalent downstream and laterally outside of a clinical PBS treatment field was assessed and compared to that of a DS beam.MethodsA novel silicon microdosimeter with well‐defined 3D SVs was used in this study. It was connected to low noise electronics, allowing for detection of lineal energies as low as 0.15 keV/μm. The microdosimeter was placed at various depths in a water phantom along the central axis of the proton beam, and at the distal part of the spread‐out Bragg peak (SOBP) in 0.5 mm increments. The RBE values of the pristine Bragg peak (BP) and SOBP were derived using the measured microdosimetric lineal energy spectra as inputs to the modified microdosimetric kinetic model (MKM). Geant4 simulations were performed in order to verify the calculated depth‐dose distribution from the treatment planning system (TPS) and to compare the simulated dose‐mean lineal energy to the experimental results.ResultsFor a 131 MeV PBS spot (124.6 mm R90 range in water), the measured dose‐mean lineal energy increased from 2 keV/μm at the entrance to 8 keV/μm in the BP, with a maximum value of 10 keV/μm at the distal edge. The derived RBE distribution for the PBS beam slowly increased from 0.97 ± 0.14 at the entrance to 1.04 ± 0.09 proximal to the BP, then to 1.1 ± 0.08 in the BP, and steeply rose to 1.57 ± 0.19 at the distal part of the BP. The RBE distribution for the DS SOBP beam was approximately 0.96 ± 0.16 to 1.01 ± 0.16 at shallow depths, and 1.01 ± 0.16 to 1.28 ± 0.17 within the SOBP. The RBE significantly increased from 1.29 ± 0.17 to 1.43 ± 0.18 at the distal edge of the SOBP.ConclusionsThe SOI microdosimeter with its well‐defined 3D SV has applicability in characterizing proton radiation fields and can measure relevant physical parameters to model the RBE with submillimeter spatial resolution. It has been shown that for a physical dose of 1.82 Gy at the BP, the derived RBE based on the MKM model increased from 1.14 to 1.6 in the BP and its distal part. Good agreement was observed between the experimental and simulation results, confirming the potential application of SOI microdosimeter with 3D SV for quality assurance in proton therapy.
Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci
McDonnell, Shannon K. , Fogarty, Zachary C. , Cheville, John C. , Riska, Shaun M., Baheti, Saurabh , Weber, Alexandra M. , Nair, Asha, O’Brien, Daniel R. , Davila, Jaime , Schaid, Daniel J. , Thibodeau, Stephen N. , Fogarty, Zach, Riska, Shaun, Nair, Asha A, Fogarty, Zachary C , Davila, Jaime I , Larson, Nicholas B. , Larson, Melissa C. , Wang, Liang , McDonnell, Shannon K

Mayo Clinic

Oncotarget | September 8, 2017 | Volume: 8 | Issue: 49 | Pages: 85896-85908

10.18632/oncotarget.20717 | PMID 29156765 Get It

Dectin-2 Is a C-Type Lectin Receptor that Recognizes Pneumocystis and Participates in Innate Immune Responses
Hebrink, Deanne, Jenson, Paige E., Marsolek, Paige L., Wüthrich, Marcel , Wang, Huafeng , Kottom, Theodore J. , Hebrink, Deanne M, Klein, Bruce S. , Yamasaki, Sho , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | September 8, 2017 | Volume: 58 | Issue: 2 | Pages: 232-240

10.1165/rcmb.2016-0335oc | PMID 28886250 Get It

Abstract Pneumocystis is an important fungal pathogen that causes life-threatening pneumonia in patients with AIDS and malignancy. Lung fungal pathogens are recognized by C-type lectin receptors (CLRs), which bind specific ligands and stimulate innate immune responses. The CLR Dectin-1 was previously shown to mediate immune responses to Pneumocystis spp. For this reason, we investigated a potential role for Dectin-2. Rats with Pneumocystis pneumonia (PCP) exhibited elevated Dectin-2 mRNA levels. Soluble Dectin-2 carbohydrate-recognition domain fusion protein showed binding to intact Pneumocystis carinii (Pc) and to native Pneumocystis major surface glycoprotein/glycoprotein A (Msg/gpA). RAW macrophage cells expressing V5-tagged Dectin-2 displayed enhanced binding to Pc and increased protein tyrosine phosphorylation. Furthermore, the binding of Pc to Dectin-2 resulted in Fc receptor-γ–mediated intracellular signaling. Alveolar macrophages from Dectin-2–deficient mice (Dectin-2−/−) showed significant decreases in phospho-Syk activation after challenge with Pc cell wall components. Stimulation of Dectin-2−/− alveolar macrophages with Pc components showed significant decreases in the proinflammatory cytokines IL-6 and TNF-α. Finally, during infection with Pneumocystis murina, Dectin-2−/− mice displayed downregulated mRNA expression profiles of other CLRs implicated in fungal immunity. Although Dectin-2−/− alveolar macrophages had reduced proinflammatory cytokine release in vitro, Dectin-2−/− deficiency did not reduce the overall resistance of these mice in the PCP model, and organism burdens were statistically similar in the long-term immunocompromised and short-term immunocompetent PCP models. These results suggest that Dectin-2 participates in the initial innate immune signaling response to Pneumocystis, but its deficiency does not impair resistance to the organism.
Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype
Gerkin, Richard C. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Dugger, Brittany N. , Belden, Christine M. , Smith, Brian H. , Sue, Lucia I., Davis, Kathryn, Zamrini, Edward , Beach, Thomas G. , Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel , Serrano, Geidy E. , Dugger, Brittany N

Mayo Clinic

Annals of Clinical and Translational Neurology | September 8, 2017 | Volume: 4 | Issue: 10 | Pages: 714-721

10.1002/acn3.447 | PMID 29046880 Get It

AbstractObjectiveTo assess the predictive potential of the complete response pattern from the University of Pennsylvania Smell Identification Test for the diagnosis of Parkinson's disease.MethodsWe analyzed a large dataset from the Arizona Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study of health and disease in elderly volunteers. Using the complete pattern of responses to all 40 items in each subject's test, we built predictive models of neurodegenerative disease, and we validated these models out of sample by comparing model predictions against postmortem pathological diagnosis.ResultsConsistent with anatomical considerations, we found that the specific test response pattern had additional predictive power compared with a conventional measure – total test score – in Parkinson's disease, but not Alzheimer's disease. We also identified specific test questions that carry the greatest predictive power for disease diagnosis.InterpretationOlfactory ability has typically been assessed with either self‐report or total score on a multiple choice test. We showed that a more accurate clinical diagnosis can be made using the pattern of responses to all the test questions, and validated this against the “gold standard” of pathological diagnosis. Information in the response pattern also suggests specific modifications to the standard test that may optimize predictive power under the typical clinical constraint of limited time. We recommend that future studies retain the individual item responses for each subject, and not just the total score, both to enable more accurate diagnosis and to enable additional future insights.
The addition of duraplasty to posterior fossa decompression in the surgical treatment of pediatric Chiari malformation Type I: a systematic review and meta-analysis of surgical and performance outcomes
Lu, Victor M. , Crowley, Sean Patrick, Phan, Kevin H. , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | September 8, 2017 | Volume: 20 | Issue: 5 | Pages: 439-449

10.3171/2017.6.peds16367 | PMID 28885133 Get It

OBJECTIVESurgery is the definitive treatment of Chiari malformation Type I (CM-I). It involves posterior fossa decompression, which can be performed along with C-1 laminectomy, reconstructive duraplasty, or tonsil shrinkage. The aim of this study was to provide an updated systematic review and meta-analysis of the latest available evidence regarding posterior fossa decompression only (PFDO) versus posterior fossa decompression with duraplasty (PFDD) in the treatment of CM-I in children.METHODSA literature search was performed in compliance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for article identification, screening, eligibility, and inclusion. Relevant articles were identified from 6 electronic databases from their inception to April 2016. These articles were screened against established criteria for inclusion into this study.RESULTSFrom 12 relevant studies identified, 1492 pediatric patients treated via PFDD were compared with 1963 pediatric patients treated by PFDO for CM-I. PFDD was associated with greater overall clinical improvement (p = 0.009), along with longer length of stay (p < 0.0001) and more postoperative complications (p = 0.0001) compared with PFDO. No difference was observed between PFDD and PFDO in terms of revision surgery incidence (p = 0.13), estimated blood loss (p = 0.14), syrinx improvement (p = 0.09), or scoliosis improvement (p = 0.95).CONCLUSIONSIt appears that the addition of duraplasty to posterior decompression in the definitive treatment of CM-I in children may alter surgical and performance outcomes. In particular, parameters of overall clinical improvement, length of stay, and postoperative complication may differ between children undergoing PFDD and those undergoing PFDO. Current evidence in the literature is of low to very low quality that, as of yet, has not been able to completely control for inherent selection bias both in study design and surgeon preference. Future, large prospective registries and randomized controlled trials are warranted to validate the findings of this study.
Final Diagnosis of 112 Girls Presenting With Genital Mucocutaneous Symptoms and Signs: The Mayo Clinic Experience
Fahy, Caoimhe, Torgerson, Rochelle R. , Davis, Mark D.P. , Fahy, Caoimhe M R

Mayo Clinic

Pediatric Dermatology | September 8, 2017 | Volume: 34 | Issue: 5 | Pages: No page available

10.1111/pde.13247 | PMID 28884911 Get It

AbstractPediatric genital mucocutaneous diseases are rare. A retrospective review was performed of children presenting with symptomatology of genital dermatoses to a hospital‐based dermatology service. This study highlights that the range of genital diseases in children is not as broad as in adults. The diagnosis of genital mucocutaneous disease in children is usually genital lichen sclerosus, but other diagnoses should be considered.
Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta‐analysis
Babary, Hamayon, Liu, Xibei , Ayatollahi, Yosef, Chen, Xin P., Doo, Loomee, Uppaluru, Lakshmi K., Kwak, Myoung Kwan, Kulaga, Catherine, Modjinou, Dodji, Olech, Ewa , Yoo, Ji Won , Yoo, Ji W

Mayo Clinic

International Journal of Rheumatic Diseases | September 8, 2017 | Volume: 21 | Issue: 1 | Pages: 84-92

10.1111/1756-185x.13159 | PMID 28884965 Get It

AbstractAimsHydroxychloroquine (HCQ) has shown to have significant immunomodulatory effects in the treatment of systemic lupus erythematosus (SLE). Current studies show favorable effects of HCQ on traditional cardiac risk factors in patients with SLE. This review examined the effects of HCQ on serum low‐density lipoprotein (LDL) level in patients with SLE.MethodsA systematic search of seven major literature search databases from their inception until 3 April, 2017 identified nine studies. Random‐effects pooled mean difference with corresponding 95% confidence intervals (CI) were estimated. Heterogeneity was measured by I2. Publication bias was assessed by visual inspection of funnel plots. Sensitivity analysis examined whether HCQ effect on serum total cholesterol level was similar to the main analysis. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the overall quality of evidence.ResultsPooled study participants were 559 patients from eight observation studies (two before‐after studies; six case‐control studies) examining the effects of HCQ on serum LDL. Pooled study participants' characteristics were as follows: mean age 45.719, female 95.262%, and prednisone use 58.366%. HCQ reduced mean LDL levels by 24.397 mg/dL (95% CI 8.921–39.872; P = 0.002). The number of studies identifying statin use was too few to perform meta‐regression analysis of statin use. Heterogeneity was extensive (I2 = 94.739%). Symmetrical funnel plot visualized no evidence of publication bias.ConclusionHCQ was associated with serum LDL level reduction by mean 24.397 mg/dL in patients with SLE. Future prospective studies are need to fully characterize the treatment effect.
Board Walk – September 2017
Dodick, David W.

Mayo Clinic

Cephalalgia | September 8, 2017 | Volume: 37 | Issue: 10 | Pages: 1009-1010

10.1177/0333102417722483 | PMID 28885053 Get It